
    
      GMX1777 will be administered as 3-Hour Infusions in Combination with Temozolomide taken
      orally for the treatment of Metastatic Melanoma. GMX1777 infusion will be given on either day
      1, days 1 and 3, or days 1,3, and 5 every 4 weeks. Temozolomide will be administered on 5
      consecutive days every 4 weeks. No investigational or commercial agents or therapies other
      than those described may be administered with the intent to treat the patient's malignancy.
    
  